Thus, our data suggest that an EGFR‐TRAF4‐MEKK3‐ERK5 axis promotes the proliferation of tumor cells, and this may be a potential target for therapeutic intervention of NSCLC. The gene discussed is MAPK7; the disease is neoplasm.